GONUTS has been updated to MW1.31 Most things seem to be working but be sure to report problems.

Have any questions? Please email us at ecoliwiki@gmail.com

PMID:15741222

From GONUTS
Jump to: navigation, search
Citation

Yabu, T, Tomimoto, H, Taguchi, Y, Yamaoka, S, Igarashi, Y and Okazaki, T (2005) Thalidomide-induced antiangiogenic action is mediated by ceramide through depletion of VEGF receptors, and is antagonized by sphingosine-1-phosphate. Blood 106:125-34

Abstract

Thalidomide, which is clinically recognized as an efficient therapeutic agent for multiple myeloma, has been thought to exert antiangiogenic action through an unknown mechanism. We here show a novel mechanism of thalidomide-induced antiangiogenesis in zebrafish embryos. Thalidomide induces the defect of major blood vessels, which is demonstrated by their morphologic loss and confirmed by the depletion of vascular endothelial growth factor (VEGF) receptors such as neuropilin-1 and Flk-1. Transient increase of ceramide content through activation of neutral sphingomyelinase (nSMase) precedes thalidomide-induced vascular defect in the embryos. Synthetic cell permeable ceramide, N-acetylsphingosine (C2-ceramide) inhibits embryonic angiogenesis as well as thalidomide. The blockade of ceramide generation by antisense morpholino oligonucleotides for nSMase prevents thalidomide-induced ceramide generation and vascular defect. In contrast to ceramide, sphingosine-1-phosphate (S1P) inhibits nSMase-dependent ceramide generation and restores thalidomide-induced embryonic vascular defect with an increase of expression of VEGF receptors. In human umbilical vein endothelial cells (HUVECs), thalidomide-induced inhibition of cell growth, generation of ceramide through nSMase, and depletion of VEGF receptors are restored to the control levels by pretreatment with S1P. These results suggest that thalidomide-induced antiangiogenic action is regulated by the balance between ceramide and S1P signal.

Links

PubMed Online version:10.1182/blood-2004-09-3679

Keywords

Angiogenesis Inhibitors/pharmacology; Animals; DNA, Complementary; Embryo, Nonmammalian/drug effects; Endothelium, Vascular/cytology; Eye Abnormalities/chemically induced; Humans; Lysophospholipids/metabolism; Magnesium/metabolism; Neuropilin-1/metabolism; Oligonucleotides, Antisense; Sphingomyelin Phosphodiesterase/genetics; Sphingomyelin Phosphodiesterase/metabolism; Sphingosine/analogs & derivatives; Sphingosine/metabolism; Sphingosine/pharmacology; Thalidomide/pharmacology; Umbilical Veins/cytology; Vascular Endothelial Growth Factor Receptor-2/metabolism; Zebrafish

Significance

Annotations

Gene product Qualifier GO Term Evidence Code with/from Aspect Extension Notes Status

DANRE:B3DIS9

enables

GO:0004767: sphingomyelin phosphodiesterase activity

ECO:0000315: mutant phenotype evidence used in manual assertion

ZFIN:ZDB-MRPHLNO-051014-1

F

Seeded From UniProt

complete

DANRE:B3DIS9

involved_in

GO:0071466: cellular response to xenobiotic stimulus

ECO:0000315: mutant phenotype evidence used in manual assertion

ZFIN:ZDB-MRPHLNO-051014-1

P

Seeded From UniProt

complete

DANRE:F1QUD7

enables

GO:0004767: sphingomyelin phosphodiesterase activity

ECO:0000315: mutant phenotype evidence used in manual assertion

ZFIN:ZDB-MRPHLNO-051014-1

F

Seeded From UniProt

complete

DANRE:F1QUD7

involved_in

GO:0071466: cellular response to xenobiotic stimulus

ECO:0000315: mutant phenotype evidence used in manual assertion

ZFIN:ZDB-MRPHLNO-051014-1

P

Seeded From UniProt

complete

DANRE:Q4LEU0

enables

GO:0004767: sphingomyelin phosphodiesterase activity

ECO:0000315: mutant phenotype evidence used in manual assertion

ZFIN:ZDB-MRPHLNO-051014-1

F

Seeded From UniProt

complete

DANRE:Q4LEU0

involved_in

GO:0071466: cellular response to xenobiotic stimulus

ECO:0000315: mutant phenotype evidence used in manual assertion

ZFIN:ZDB-MRPHLNO-051014-1

P

Seeded From UniProt

complete


See also

References

See Help:References for how to manage references in GONUTS.